vs

Side-by-side financial comparison of Silence Therapeutics plc (SLN) and WESTPORT FUEL SYSTEMS INC. (WPRT). Click either name above to swap in a different company.

Silence Therapeutics plc is the larger business by last-quarter revenue ($15.7M vs $12.5M, roughly 1.3× WESTPORT FUEL SYSTEMS INC.). Silence Therapeutics plc runs the higher net margin — -14.7% vs -274.8%, a 260.1% gap on every dollar of revenue.

Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid (siRNA) therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.

Westport Innovations is a company that develops alternative fuel, low-emissions technologies to allow engines to operate on clean-burning fuels such as compressed natural gas (CNG), liquefied natural gas (LNG), hydrogen and biofuels such as landfill gas. Headquartered in Vancouver, British Columbia, Canada, where the company was founded, Westport also has facilities in France, Sweden, Italy, China, Australia and the United States.

SLN vs WPRT — Head-to-Head

Bigger by revenue
SLN
SLN
1.3× larger
SLN
$15.7M
$12.5M
WPRT
Higher net margin
SLN
SLN
260.1% more per $
SLN
-14.7%
-274.8%
WPRT

Income Statement — Q1 FY2024 vs Q2 FY2025

Metric
SLN
SLN
WPRT
WPRT
Revenue
$15.7M
$12.5M
Net Profit
$-2.3M
$-34.3M
Gross Margin
82.2%
6.7%
Operating Margin
-35.6%
-8.1%
Net Margin
-14.7%
-274.8%
Revenue YoY
-11.4%
Net Profit YoY
-690.4%
EPS (diluted)
$-0.02
$-1.98

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SLN
SLN
WPRT
WPRT
Q2 25
$12.5M
Q3 24
$4.9M
Q2 24
$14.1M
Q1 24
$15.7M
Net Profit
SLN
SLN
WPRT
WPRT
Q2 25
$-34.3M
Q3 24
$-3.9M
Q2 24
$5.8M
Q1 24
$-2.3M
Gross Margin
SLN
SLN
WPRT
WPRT
Q2 25
6.7%
Q3 24
13.6%
Q2 24
16.7%
Q1 24
82.2%
Operating Margin
SLN
SLN
WPRT
WPRT
Q2 25
-8.1%
Q3 24
-43.9%
Q2 24
-54.9%
Q1 24
-35.6%
Net Margin
SLN
SLN
WPRT
WPRT
Q2 25
-274.8%
Q3 24
-79.3%
Q2 24
41.2%
Q1 24
-14.7%
EPS (diluted)
SLN
SLN
WPRT
WPRT
Q2 25
$-1.98
Q3 24
$-0.22
Q2 24
$0.34
Q1 24
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SLN
SLN
WPRT
WPRT
Cash + ST InvestmentsLiquidity on hand
$6.1M
Total DebtLower is stronger
$977.0K
Stockholders' EquityBook value
$156.8M
$108.9M
Total Assets
$272.1M
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SLN
SLN
WPRT
WPRT
Q2 25
$6.1M
Q3 24
Q2 24
Q1 24
Total Debt
SLN
SLN
WPRT
WPRT
Q2 25
$977.0K
Q3 24
Q2 24
Q1 24
Stockholders' Equity
SLN
SLN
WPRT
WPRT
Q2 25
$108.9M
Q3 24
$149.3M
Q2 24
$151.5M
Q1 24
$156.8M
Total Assets
SLN
SLN
WPRT
WPRT
Q2 25
$272.1M
Q3 24
Q2 24
Q1 24
Debt / Equity
SLN
SLN
WPRT
WPRT
Q2 25
0.01×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SLN
SLN
WPRT
WPRT
Operating Cash FlowLast quarter
$-9.1M
$-5.6M
Free Cash FlowOCF − Capex
$-6.4M
FCF MarginFCF / Revenue
-51.6%
Capex IntensityCapex / Revenue
0.0%
6.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SLN
SLN
WPRT
WPRT
Q2 25
$-5.6M
Q3 24
$-11.7M
Q2 24
$1.5M
Q1 24
$-9.1M
Free Cash Flow
SLN
SLN
WPRT
WPRT
Q2 25
$-6.4M
Q3 24
$-11.9M
Q2 24
$262.0K
Q1 24
FCF Margin
SLN
SLN
WPRT
WPRT
Q2 25
-51.6%
Q3 24
-243.4%
Q2 24
1.9%
Q1 24
Capex Intensity
SLN
SLN
WPRT
WPRT
Q2 25
6.6%
Q3 24
3.8%
Q2 24
8.9%
Q1 24
0.0%
Cash Conversion
SLN
SLN
WPRT
WPRT
Q2 25
Q3 24
Q2 24
0.26×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons